Thus, the revised World Health Organization classification proposed that if a demonstrable SF3B1 gene mutation is identified, MDS-RS can be diagnosed if RS comprise as few as 5% of nucleated erythroid cells; otherwise, at least 15% RS is still required for the definite diagnosis of MDS-RS13. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.